EP0910392A2 - Radicaux a anions oxygene et/ou substances therapeutiques contenant leurs produits de reaction et de degradation et leur utilisation dans le traitement de la maladie de parkinson - Google Patents

Radicaux a anions oxygene et/ou substances therapeutiques contenant leurs produits de reaction et de degradation et leur utilisation dans le traitement de la maladie de parkinson

Info

Publication number
EP0910392A2
EP0910392A2 EP98913515A EP98913515A EP0910392A2 EP 0910392 A2 EP0910392 A2 EP 0910392A2 EP 98913515 A EP98913515 A EP 98913515A EP 98913515 A EP98913515 A EP 98913515A EP 0910392 A2 EP0910392 A2 EP 0910392A2
Authority
EP
European Patent Office
Prior art keywords
parkinson
disease
oxygen anion
anion radicals
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98913515A
Other languages
German (de)
English (en)
Inventor
Naum Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goldstein & Lewin Technology GmbH
Original Assignee
Goldstein & Lewin Technology GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldstein & Lewin Technology GmbH filed Critical Goldstein & Lewin Technology GmbH
Publication of EP0910392A2 publication Critical patent/EP0910392A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides

Definitions

  • the invention relates to oxygen anion radicals (superoxide radical, abbreviated below with “SAR” or “superoxide”, • O j ) and / or their secondary and degradation products (for example H2O2, 'C ⁇ H or their hydrate clusters) containing therapeutic agents and their use for Treatment of Parkinson's disease.
  • oxygen anion radicals superoxide radical, abbreviated below with “SAR” or “superoxide”, • O j
  • SAR oxygen anion radical
  • O j oxygen anion radical
  • secondary and degradation products for example H2O2, 'C ⁇ H or their hydrate clusters
  • Parkinson's disease (“shaking paralysis") is characterized by an extrapyramidal motor syndrome, which is composed of akinesia (poor or absent facial expressions), rigidity (stiffness) and tremor (muscle tremors). Parkinson's syndrome is the most common neurological disease in advanced age; however, there are also cases of very young patients. The causes of the disease are varied, they can be damaged by z.
  • a crucial factor in the development of motor disorders is the lack of dopamine in substantia nigra neurons in the brain stem. These neurons have an inhibitory effect on cholinergic neurons in the striatum. Together with other nerves, these form the so-called nigrostriatal feedback system, which controls the spinal motor system. A decrease in dopamine concentration leads to rigidity and the other symptoms of Parkinson's disease mentioned above.
  • Parkinson's disease In addition to gymnastics, massages and psychotherapeutic treatment, therapy for Parkinson's disease also includes an individually set combination therapy for the underlying disease.
  • Substances with an effect against the motor symptoms of Parkinson's disease belong to different groups of substances. They are often derived either from atropine or from antihistamines and have cholinolytic properties, or they take effect via dopamine or dopamine receptors.
  • Rigor and akinesis are treated with L-3, 4-dihydroxyphenylalanine (L-DOPA), amantadine and memantine, while Metixen is mainly used to treat the often very persistent symptoms of tremor.
  • Parkinson's disease is treated at an early stage with Seiegin, an inhibitor of monoamine oxidase B (MAO-B).
  • MAO-B is responsible for the breakdown of dopamine in the nigrostriatal system.
  • the polypeptide GDNF neurotrophic factor [NF] formed by glia cells
  • GDNF neurotrophic factor
  • Oxygen anion radicals are generated by a device such as that described in published patent application DE 41 12 459 A1.
  • their chemical or enzymatic generation is also possible (Fridovich, I., (1970), "Quantitative aspects of the production of Superoxide anion radical by milk xanthine oxidase.” J Biol. Chem. 245, 4053).
  • the present invention has for its object to provide a suitable for the treatment of the symptoms of Parkinson's disease or other diseases associated with tremor, which does not have the disadvantages and side effects of the above-mentioned anti-Parkinson agents and in particular for the therapy of the stubborn symptoms of the tremor is suitable.
  • the object is achieved according to the invention by creating an agent which contains oxygen anion radicals and / or their degradation products and secondary products.
  • the oxygen anion radicals are generated selectively on the basis of their metastable state in a suitable device (cf., for example, DE 41 12 459 A1) or are generated selectively using a suitable chemical formulation to be applied.
  • a suitable device cf., for example, DE 41 12 459 A1
  • liposomes which serve as carriers for enzyme systems (e.g. xanthine / xanthine oxidase) and in this way generate oxygen anion radicals and their secondary products only at the destination, is advantageous.
  • oxygen anion radicals are preferably carried out with little loss by inhalation or intranasal application, the oxygen anion radicals being made available at a rate of formation of 100 pmol l " ; l s ⁇ 1 to 1 fol l -1 s _1
  • Oxygen anion radicals and / or their secondary or degradation products are, for example, perhydroxyl radicals, hydrogen peroxide, other activated oxygen species or their hydrate clusters.
  • the use of the agent according to the invention has a clear effect on the tremor, as occurs in particular in Parkinson's disease.
  • the tremor can also result from a different clinical picture.
  • the medium according to the invention is an aqueous solution containing from 10 " to 10 " mol / 1 H 2 O 2 -containing aqueous solution.
  • the novel effect on which the present invention is based, consists in a positive effect of oxygen anion radicals and / or their follow-up or breakdown products on the tremor which is difficult to treat, as is typically observed in Parkinson's disease.
  • Example 1 is intended to illustrate the novel effect of SAR on the symptoms of Parkinson's disease and in particular on the tremor that is difficult to treat.
  • Example 1 is intended to illustrate the novel effect of SAR on the symptoms of Parkinson's disease and in particular on the tremor that is difficult to treat.
  • Table 1 Determination of the activity of various types of monoamine oxidase and the content of malondialdehyde and conjugated dienes in the basal ganglia, the hypothalamus and the brain stem of rats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des radicaux à anions oxygène et/ou des substances thérapeutiques contenant leurs produits de réaction et de dégradation. L'invention concerne également leur utilisation dans le traitement de la maladie de Parkinson. Le principal objectif est de réduire ou d'éliminer les tremblements typiques de la maladie de Parkinson mais qui peuvent également apparaître avec d'autres maladies ou tout simplement sous forme de tremblements 'séniles'.
EP98913515A 1997-02-20 1998-02-17 Radicaux a anions oxygene et/ou substances therapeutiques contenant leurs produits de reaction et de degradation et leur utilisation dans le traitement de la maladie de parkinson Withdrawn EP0910392A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19708643 1997-02-20
DE1997108643 DE19708643C2 (de) 1997-02-20 1997-02-20 Verwendung von Sauerstoffanionradikalen und/oder deren Folge- und Abbauprodukte zur Behandlung von Morbus Parkinson
PCT/DE1998/000518 WO1998036758A2 (fr) 1997-02-20 1998-02-17 Radicaux a anions oxygene et/ou substances therapeutiques contenant leurs produits de reaction et de degradation et leur utilisation dans le traitement de la maladie de parkinson

Publications (1)

Publication Number Publication Date
EP0910392A2 true EP0910392A2 (fr) 1999-04-28

Family

ID=7822112

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98913515A Withdrawn EP0910392A2 (fr) 1997-02-20 1998-02-17 Radicaux a anions oxygene et/ou substances therapeutiques contenant leurs produits de reaction et de degradation et leur utilisation dans le traitement de la maladie de parkinson

Country Status (7)

Country Link
EP (1) EP0910392A2 (fr)
CN (1) CN1222856A (fr)
AU (1) AU6819898A (fr)
CA (1) CA2259986A1 (fr)
DE (1) DE19708643C2 (fr)
EA (1) EA001107B1 (fr)
WO (1) WO1998036758A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
RU2253461C1 (ru) * 2004-04-30 2005-06-10 Общество с ограниченной ответственностью "Паркинфарм" Фармацевтическая комбинация, оказывающая влияние на функционирование цнс, способ коррекции состояний, связанных с нарушениями функционирования цнс; фармацевтический набор; средство, способствующее проникновению через гематоэнцефалический барьер лекарственных субстанций и метаболитов; фармацевтическое средство для эндоназального применения

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4112459A1 (de) * 1991-04-12 1992-10-15 Naum Dr Goldstein Verfahren und einrichtung zur erzeugung von definierten ionisierten gasen bzw. gasgemischen
CA2084725A1 (fr) * 1992-02-06 1994-06-08 Albert Roussy Solution therapeutique a usage externe

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9836758A3 *

Also Published As

Publication number Publication date
CA2259986A1 (fr) 1998-08-27
WO1998036758A2 (fr) 1998-08-27
EA199800941A1 (ru) 1999-06-24
DE19708643C2 (de) 1999-04-15
WO1998036758A3 (fr) 1998-12-23
DE19708643A1 (de) 1998-08-27
AU6819898A (en) 1998-09-09
EA001107B1 (ru) 2000-10-30
CN1222856A (zh) 1999-07-14

Similar Documents

Publication Publication Date Title
DE60119534T2 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
JPH07504436A (ja) 鼻・洞機能障害の治療方法及びセイヨウワサビ製剤
CH692477A5 (de) Zusammensetzung zur Stimulation von Wiederherstellungsvorgängen, enthaltend L-Lysil-L-Glutaminsäure.
KR20090004876A (ko) 신경성 진전 조절용 국소 마취제의 신규한 용도
DE69129563T2 (de) Epidermis-Wachstumsfaktor als Arzneimittel zur Wiederherstellung der Neuronen der Substantia nigra in der Behandlung nervenzerstörender Störungen
DE19708643C2 (de) Verwendung von Sauerstoffanionradikalen und/oder deren Folge- und Abbauprodukte zur Behandlung von Morbus Parkinson
WO1999042088A2 (fr) Procede pour le traitement de maladies ou de troubles de l'oreille interne
DE60100660T2 (de) Verwendung von modafinil zur herstellung eines arzneimittels zur behandlung von vigilanzstörungen im zusammenhang mit myopathien
DE60029463T2 (de) Behandlung von dyskinesie
EP3352763B1 (fr) Substance pour la prophylaxie et le traitement d'infections provoquées par des virus influenza
Vasiliev The physiological mechanisms of aeroions
DE19855704C2 (de) Verwendung einer Wirkstoffkombination zur Behandlung der Parkinsonschen Krankheit
DE202016100357U1 (de) Pharmazeutische Zubereitung und deren Verwendung bei viralen, entzündlichen Erkrankungen der oberen Atemwege
DE60016762T2 (de) Behandlung von allergischer Rhinitis mit bestimmten vasoaktiven Amin-bindenden Proteinen
EP2218456B1 (fr) Composition de lectine pour la prophylaxie et/ou le traitement d'effets secondaires indésirables d'un médicament
DE19826628C1 (de) Intranasale Verwendung von Insulin bei Hirnleistungsstörungen
Freire-Maia et al. Pharmacological blockade of the cardiovascular and respiratory effects produced by tityustoxin in the rat
EP2740480A1 (fr) Procédé destiné à administrer du gaz hypoxique et hyperoxique
DE2633891A1 (de) Neues salz der alpha-methylbenzoyl- 5-thiophen-2-essigsaeure, verfahren zu dessen herstellung und pharmazeutische zusammensetzungen
DE602004004698T2 (de) Verwendung von Stanozolol zur Herstellung von entzündungshemmenden und antidegenerativen Arzneimitteln
DE2057174A1 (de) Pharmazeutisches Produkt,insbesondere injizierbares Lokalanaesthetikum
DE10319837A1 (de) Verwendung von Edelgasen, insbesondere Argon oder Xenon, zur Prophylaxe oder Therapie von Innenohrerkrankungen
RU2188630C1 (ru) Средство профилактики и лечения наркомании
EP1699451B1 (fr) Utilisation de silibinine avec un acide alpha-lipoique pour le traitement des broncho-pneumopathies chroniques obstructives
WO2004037291A1 (fr) Produit pharmaceutique a application endonasale pour traiter des maladies et des troubles du systeme nerveux central

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981119

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DK ES FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20000320

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020723